NVCR
Price
$12.05
Change
-$0.00 (-0.00%)
Updated
Apr 18, 6:59 PM EST
14 days until earnings call
PACB
Price
$1.46
Change
+$0.06 (+4.29%)
Updated
Apr 18, 6:59 PM EST
14 days until earnings call
Ad is loading...

Compare trend and price NVCR vs PACB

Header iconNVCR vs PACB Comparison
Open Charts NVCR vs PACBBanner chart's image
NovoCure
Price$12.05
Change-$0.00 (-0.00%)
Volume$876.29K
CapitalizationN/A
Pacific Biosciences of California
Price$1.46
Change+$0.06 (+4.29%)
Volume$11.41M
CapitalizationN/A
View a ticker or compare two or three
NVCR vs PACB Comparison Chart

Loading...

NVCRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PACBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
NVCR vs. PACB commentary
Apr 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVCR is a Hold and PACB is a Hold.

COMPARISON
Comparison
Apr 19, 2024
Stock price -- (NVCR: $12.05 vs. PACB: $1.40)
Brand notoriety: NVCR and PACB are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: NVCR: 100% vs. PACB: 354%
Market capitalization -- NVCR: $1.66B vs. PACB: $976.68M
NVCR [@Medical Specialties] is valued at $1.66B. PACB’s [@Medical Specialties] market capitalization is $976.68M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVCR’s FA Score shows that 1 FA rating(s) are green whilePACB’s FA Score has 0 green FA rating(s).

  • NVCR’s FA Score: 1 green, 4 red.
  • PACB’s FA Score: 0 green, 5 red.
According to our system of comparison, NVCR is a better buy in the long-term than PACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVCR’s TA Score shows that 4 TA indicator(s) are bullish while PACB’s TA Score has 4 bullish TA indicator(s).

  • NVCR’s TA Score: 4 bullish, 5 bearish.
  • PACB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PACB is a better buy in the short-term than NVCR.

Price Growth

NVCR (@Medical Specialties) experienced а -17.58% price change this week, while PACB (@Medical Specialties) price change was -57.96% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -3.86%. For the same industry, the average monthly price growth was -3.97%, and the average quarterly price growth was +9.68%.

Reported Earning Dates

NVCR is expected to report earnings on Jul 25, 2024.

PACB is expected to report earnings on Jul 31, 2024.

Industries' Descriptions

@Medical Specialties (-3.86% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for NVCR with price predictions.
OPEN
A.I.dvisor published
a Summary for PACB with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
NVCR($1.66B) has a higher market cap than PACB($977M). NVCR YTD gains are higher at: -19.290 vs. PACB (-85.729). NVCR has higher annual earnings (EBITDA): -177.45M vs. PACB (-277.28M). NVCR has more cash in the bank: 911M vs. PACB (631M). NVCR has less debt than PACB: NVCR (596M) vs PACB (934M). NVCR has higher revenues than PACB: NVCR (509M) vs PACB (201M).
NVCRPACBNVCR / PACB
Capitalization1.66B977M170%
EBITDA-177.45M-277.28M64%
Gain YTD-19.290-85.72923%
P/E RatioN/AN/A-
Revenue509M201M253%
Total Cash911M631M144%
Total Debt596M934M64%
FUNDAMENTALS RATINGS
NVCR vs PACB: Fundamental Ratings
NVCR
PACB
OUTLOOK RATING
1..100
725
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
6598
P/E GROWTH RATING
1..100
1075
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVCR's Valuation (100) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that NVCR’s stock grew similarly to PACB’s over the last 12 months.

NVCR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that NVCR’s stock grew similarly to PACB’s over the last 12 months.

NVCR's SMR Rating (97) in the Medical Specialties industry is in the same range as PACB (97) in the Biotechnology industry. This means that NVCR’s stock grew similarly to PACB’s over the last 12 months.

NVCR's Price Growth Rating (65) in the Medical Specialties industry is somewhat better than the same rating for PACB (98) in the Biotechnology industry. This means that NVCR’s stock grew somewhat faster than PACB’s over the last 12 months.

NVCR's P/E Growth Rating (10) in the Medical Specialties industry is somewhat better than the same rating for PACB (75) in the Biotechnology industry. This means that NVCR’s stock grew somewhat faster than PACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVCRPACB
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 22 days ago
77%
Bullish Trend 22 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
NVCRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PACBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VCRIX11.730.07
+0.60%
MainStay CBRE Global Infrastructure I
FWBTX13.38N/A
N/A
Fidelity Advisor Multi-Asset Income C
ARAOX14.69-0.03
-0.20%
Aristotle/Saul Global Eq A
PMSBX33.42-0.12
-0.36%
Principal MidCap R1
SSDAX30.73-0.36
-1.16%
DWS Small Cap Growth A

NVCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVCR has been loosely correlated with NVRO. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if NVCR jumps, then NVRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVCR
1D Price
Change %
NVCR100%
-3.29%
NVRO - NVCR
40%
Loosely correlated
-3.23%
VCYT - NVCR
35%
Loosely correlated
-0.32%
ILMN - NVCR
31%
Poorly correlated
+0.51%
SINT - NVCR
30%
Poorly correlated
+62.88%
RVTY - NVCR
30%
Poorly correlated
+0.27%
More

PACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PACB has been loosely correlated with MASI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then MASI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PACB
1D Price
Change %
PACB100%
N/A
MASI - PACB
58%
Loosely correlated
-1.13%
TWST - PACB
56%
Loosely correlated
-0.14%
IQV - PACB
48%
Loosely correlated
-0.82%
INMD - PACB
40%
Loosely correlated
-0.96%
KIDS - PACB
39%
Loosely correlated
-0.93%
More